(R)-OR-S1
| Code | Size | Price |
|---|
| TAR-T23575-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
(R)-OR-S1 is a SAM-competitive, highly selective, orally bioavailable dual inhibitor of EZH1/2.
CAS:
1809336-19-3
Formula:
C26H34BrN3O4
Molecular Weight:
532.479
Purity:
0.98
SMILES:
CN(C)[C@H]1CC[C@@H](CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Br)C(=O)NCc1c(C)cc(C)[nH]c1=O
References
1. Zhang H, Dou Y. Reprogram Murine Epiblast Stem Cells by Epigenetic Inhibitors. Bio Protoc. 2017 Mar 5;7(5). pii: e2168. doi: 10.21769/BioProtoc.2168. PubMed PMID: 29082293; PubMed Central PMCID: PMC5659616.
2. Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y, Yang J, Huang L, Bernard D, Xu J, Townsend EC, Cao F, Ran X, Li X, Wen B, Sun D, Stuckey JA, Lei M, Dou Y, Wang S. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem. 2017 Jun 22;60(12):4818-4839. doi: 10.1021/acs.jmedchem.6b01796. Epub 2017 Jun 12. PubMed PMID: 28603984.
3. Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T. Targeting human SET1/MLL family of proteins. Protein Sci. 2017 Apr;26(4):662-676. doi: 10.1002/pro.3129. Epub 2017 Mar 6. Review. PubMed PMID: 28160335; PubMed Central PMCID: PMC5368065.
4. Muller S, Nayak A. Inhibition of MLL1 histone methyltransferase brings the developmental clock back to na?ve pluripotency. Stem Cell Investig. 2016 Oct 20;3:58. eCollection 2016. PubMed PMID: 27868040; PubMed Central PMCID: PMC5104571.